Componentes:
Método de ação:
Opção de tratamento:
Medicamente revisado por Militian Inessa Mesropovna, Farmácia Última atualização em 08.04.2022
Atenção! As informações na página são apenas para profissionais de saúde! As informações são coletadas em fontes abertas e podem conter erros significativos! Tenha cuidado e verifique novamente todas as informações desta página!
20 principais medicamentos com os mesmos componentes:
20 principais medicamentos com os mesmos tratamentos:
Treatment of moderate to severe pain.
Adults
ULTRAM® (tramadol hydrochloride) is indicated for the management of moderate to moderately severe pain in adults.
Geriatrics ( > 65 Years of Age)
Healthy elderly subjects aged 65 to 75 years administered tramadol have plasma concentrations and elimination half-lives comparable to those observed in healthy subjects less than 65 years of age. ULTRAM® should be administered with greater caution in patients older than 75 years, due to the greater potential for adverse events in this population (see WARNINGS AND PRECAUTIONS, DOSAGE AND ADMINISTRATION).
Pediatrics ( < 18 Years of Age)
The safety and effectiveness of ULTRAM® have not been studied in the pediatric population. Therefore, use of ULTRAM® tablets is not recommended in patients under 18 years of age.
Treatment of moderate to severe pain.
These tablets are indicated in adults and adolescents aged 12 years and above.
Orozamudol is indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.
Adults
Orozamudol® (tramadol hydrochloride) is indicated for the management of moderate to moderately severe pain in adults.
Geriatrics ( > 65 Years of Age)
Healthy elderly subjects aged 65 to 75 years administered tramadol have plasma concentrations and elimination half-lives comparable to those observed in healthy subjects less than 65 years of age. Orozamudol® should be administered with greater caution in patients older than 75 years, due to the greater potential for adverse events in this population (see WARNINGS AND PRECAUTIONS, DOSAGE AND ADMINISTRATION).
Pediatrics ( < 18 Years of Age)
The safety and effectiveness of Orozamudol® have not been studied in the pediatric population. Therefore, use of Orozamudol® tablets is not recommended in patients under 18 years of age.